Pfizer, Astellas prostate cancer drug promising in late-stage trial


Pfizer Inc and Japan's Astellas Pharma Inc said on Thursday their blockbuster prostate cancer drug met the main goal of a key study that tested it for treating the disease in its early stages. The positive data sets the stage for an earlier-than-expected approval of the drug, which is already cleared to treat metastatic castration-resistant prostate cancer - where the cancer has spread to other parts of the body.



from Biotech News